Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).

Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).

Abstract: The compounds of Formula I, II, and III along with their stereoisomers, pharmaceutically acceptable salts, polymorphs, solvates and hydrates thereof are described in the present disclosure. The said compounds restore immune activation in case of infections or a disease associated with an HIV infection in a subject in need thereof.

Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).

Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).

Abstract: A method for prevention and/or treatment of diminution of bone tissue using a composition comprising a compound selected from Withaferin A (WFA), Withanolide A, and Withanone. The composition showed enhanced WFA bioavailability in rodents against plain WFA, promotes bone marrow cell differentiation, and increases the percent of bone volume to tissue volume (BV/TV %) by 3 folds as compared to free Withaferin A (WFA).

Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).

Abstract: Systems, apparatuses, services, platforms, and methods are discussed herein that provide assistance for user interface devices. In one example, an assistance application is provided comprising an imaging system configured to capture an image of a scene, an interface system configured to provide data associated with the image to a distributed assistance service that responsively processes the data to recognize properties of the scene and establish feedback for a user based at least on the properties of the scene, and a user interface configured to provide the feedback to the user.

Abstract: A method for prevention and/or treatment of diminution of bone tissue using a composition comprising a compound selected from Withaferin A (WFA), Withanolide A, and Withanone. The composition showed enhanced WFA bioavailability in rodents against plain WFA, promotes bone marrow cell differentiation, and increases the percent of bone volume to tissue volume (BV/TV%) by 3 folds as compared to free Withaferin A (WFA).

Abstract: A method, system, and/or computer program product automatically abstracts and selects an optimal set of variance-related features that are indicative of an individual outcome and personalized plan selection in health care. An abstracted set of candidate variance-related patient features, which comprise temporally heteroskedastic features, is generated. Each patient feature from the abstracted set of candidate variance-related patient features is optimized by identifying a time period in which variances and heteroskedasticity of each patient feature are maximized, where the optimizing creates an optimal abstracted set of variance-related patient features from the time period in which the variances and heteroskedasticity of each patient feature are maximized. The optimal abstracted set of variance-related patient features is then used for a current patient to predict a particular outcome and/or to create a personalized health care treatment plan.